Aktuellt
SENASTE
Calliditas delivers a positive surprise in total sales, including royalty contributions from Asia, US patient enrollment (in line with our expectations), and new subscribers (15% above our expectations). The actual US sales growth during H1 is positive at >70%, which is reassuring, and it makes sense to measure H1 growth as Q1 was indirectly impacted by the cyberattack with some reversal during Q2. Calliditas enters H2 with a very positive momentum.
LÄS MER
